DF
Therapeutic Areas
Genscript Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cilta-cel (ciltacabtagene autoleucel) | Relapsed/Refractory Multiple Myeloma | Approved |
| LB1901 | Relapsed/Refractory T-cell Lymphoma | Phase 1 |
| LB1905 | Relapsed/Refractory Gastric Cancer | Phase 1 |
| LB2102 | Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 |
| LB-Multi (Multi-targeted CAR-T) | Solid Tumors | Pre-clinical |
| TCR-T Programs | Solid Tumors | Pre-clinical |
Leadership Team at Genscript Biotech
DR
Dr. Robert (Bob) T. Yuan
Chief Executive Officer
DL
Dr. Lily (Lihua) Wang
Chief Financial Officer, Senior Vice President
DB
Dr. Brian Min
Chief Strategy Officer, Senior Vice President
DF
Dr. Fang (Fred) Wang
Chief Technology Officer, Senior Vice President
DS
Dr. S. Jack Yi
Chief Scientific Officer, Genscript Biotech USA
DC
Dr. Changgeng Qian
Chief Operating Officer, Genscript ProBio
DL
Dr. Lei (Louis) Wang
Senior Vice President, Head of Global Marketing and Sales
DH
Dr. Hong (Henry) Ji
Independent Non-Executive Director
DZ
Dr. Zhenping (ZP) Zhu
Scientific Founder, former Chief Scientific Officer